AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OrganovoPharmacyte BiotechMicrobot MedicalIdera PharmaceuticalsGenocea Biosciences
SymbolNASDAQ:ONVOOTCMKTS:PMCBNASDAQ:MBOTNASDAQ:IDRANASDAQ:GNCA
Price Information
Current Price$0.71$0.02$7.36$2.00$2.61
52 Week RangeHoldN/ABuyBuyBuy
Beat the Market™ Rank
Overall Score0.70.51.32.01.6
Analysis Score0.00.03.53.53.5
Community Score2.52.42.82.82.8
Dividend Score0.00.00.00.00.0
Ownership Score1.00.00.03.01.0
Earnings & Valuation Score0.00.00.00.60.6
Analyst Ratings
Consensus RecommendationHoldN/ABuyBuyBuy
Consensus Price TargetN/AN/A$19.00$8.00$16.33
% Upside from Price TargetN/AN/A158.15% upside300.00% upside525.80% upside
Trade Information
Market Cap$89.92 million$30.31 million$53.25 million$69.43 million$73.80 million
Beta1.181.514.352.112.26
Average Volume1,089,0344,723,149527,542228,879309,383
Sales & Book Value
Annual Revenue$2.20 millionN/AN/A$1.45 millionN/A
Price / Sales42.13N/AN/A46.49N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.20 per shareN/A$5.02 per share($0.39) per share$0.89 per share
Price / Book3.55N/AN/A-5.13N/A
Profitability
Net Income$-18,710,000.00$-4,070,000.00$-7,250,000.00$-56,510,000.00$-38,950,000.00
EPSN/AN/AN/A($1.57)($2.09)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-798.68%N/AN/AN/AN/A
Return on Equity (ROE)-60.96%-89.24%-39.63%-102.25%-152.70%
Return on Assets (ROA)-53.10%-76.41%-32.53%-41.09%-70.41%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.02%N/A1.28%
Current Ratio15.65%0.21%32.47%1.05%1.98%
Quick Ratio15.65%0.21%32.47%1.05%1.98%
Ownership Information
Institutional Ownership Percentage50.16%0.03%10.73%25.83%50.27%
Insider Ownership Percentage4.20%N/A14.47%3.50%2.08%
Miscellaneous
Employees70493661
Shares Outstanding130.56 million1.64 billion7.10 million33.70 million27.64 million
Next Earnings DateN/A8/10/2020 (Estimated)6/3/2020 (Estimated)8/13/2020 (Estimated)7/23/2020 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.